Trial Profile
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) III
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-689
- Sponsors Merck Sharp & Dohme Corp.
- 21 Sep 2023 Planned End Date changed from 30 Jul 2026 to 10 Sep 2026.
- 21 Sep 2023 Planned primary completion date changed from 30 Jul 2025 to 10 Sep 2025.
- 13 Mar 2021 This trial has been suspended in Spain, according to European Clinical Trials Database record.